Pedro N Aguiar1, Ilka Lopes Santoro1, Hakaru Tadokoro1, Gilberto de Lima Lopes2,3, Bruno Andraus Filardi1, Pedro Oliveira4, Giannis Mountzios5, Ramon Andrade de Mello6,7. 1. Division of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil. 2. Oncoclínicas do Brasil group, São Paulo, Brazil. 3. Department of Medical Oncology, Johns Hopkins University, Singapore. 4. Department of Population Studies, Abel Salazar Biomedical Institute, University of Porto, Porto, Portugal. 5. Department of Medical Oncology, University of Athens School of Medicine, Athens, Greece. 6. Department of Biomedical Sciences & Medicine, University of Algarve, Faro, Portugal. 7. Faculty of Medicine, University of Porto, Porto, Portugal.
Abstract
BACKGROUND: Tumor programmed death ligand one (PD-L1) expression has been studied in several trials in non-small-cell lung cancer. METHODS: We assessed the potential role of PD-L1 expression according to Cochrane Collaboration's Guidelines. RESULTS: 13 studies with 1979 patients were included. Among 915 PD-L1 negative patients this rate was 13% (RR 2.08; 95% CI: 1.49-2.91; p < 0.01). The response rate has increased concurrent to the PD-L1 expression (Pearson's correlation, r = 0.43). PD-L1 expression was also related to better 24-weeks progression-free rate (RR 0.79; 95% CI: 0.71-0.89) and a trend toward better 1-year overall survival rate (RR 0.96; 95% CI: 0.87-1.06). CONCLUSION: Taking this data in account, PD-L1 overexpression could not be currently considered a robust biomarker to tailor the immune checkpoint inhibitors treatment.
BACKGROUND: Tumor programmed death ligand one (PD-L1) expression has been studied in several trials in non-small-cell lung cancer. METHODS: We assessed the potential role of PD-L1 expression according to Cochrane Collaboration's Guidelines. RESULTS: 13 studies with 1979 patients were included. Among 915 PD-L1 negative patients this rate was 13% (RR 2.08; 95% CI: 1.49-2.91; p < 0.01). The response rate has increased concurrent to the PD-L1 expression (Pearson's correlation, r = 0.43). PD-L1 expression was also related to better 24-weeks progression-free rate (RR 0.79; 95% CI: 0.71-0.89) and a trend toward better 1-year overall survival rate (RR 0.96; 95% CI: 0.87-1.06). CONCLUSION: Taking this data in account, PD-L1 overexpression could not be currently considered a robust biomarker to tailor the immune checkpoint inhibitors treatment.
Authors: Soo Jung Lee; Sun-Young Jun; In Hee Lee; Byung Woog Kang; Su Yeon Park; Hye Jin Kim; Jun Seok Park; Gyu-Seog Choi; Ghilsuk Yoon; Jong Gwang Kim Journal: J Cancer Res Clin Oncol Date: 2018-03-08 Impact factor: 4.553
Authors: Howard L Kaufman; Jeffery Russell; Omid Hamid; Shailender Bhatia; Patrick Terheyden; Sandra P D'Angelo; Kent C Shih; Céleste Lebbé; Gerald P Linette; Michele Milella; Isaac Brownell; Karl D Lewis; Jochen H Lorch; Kevin Chin; Lisa Mahnke; Anja von Heydebreck; Jean-Marie Cuillerot; Paul Nghiem Journal: Lancet Oncol Date: 2016-09-01 Impact factor: 41.316
Authors: Dirk De Ruysscher; Jianyue Jin; Tim Lautenschlaeger; Jin-Xiong She; Zhongxing Liao; Feng-Ming Spring Kong Journal: Transl Lung Cancer Res Date: 2017-12